Therapeutic interactions between mesenchymal stem cells for healing medication-related osteonecrosis of the jaw
Authors:
- Yuri MatsuuraYMYuri Matsuura
- Ikiru AtsutaIAIkiru Atsuta
- Yasunori AyukawaYAYasunori Ayukawa
- Takayoshi YamazaTYTakayoshi Yamaza
- Ryosuke KondoRKRyosuke Kondo
- Akira TakahashiATAkira Takahashi
- Nobuyuki UedaNUNobuyuki Ueda
- Wakana OshiroWOWakana Oshiro
- Yoshihiro TsukiyamaYTYoshihiro Tsukiyama
- Kiyoshi KoyanoKKKiyoshi Koyano
Open Access
- 17 August 2016
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 7 (1) , 119
Abstract
Background: Mesenchymal stem cells (MSCs) have been isolated from a variety of tissues, including bone marrow, adipose, and mucosa. MSCs have the capacity for self-renewal and differentiation. Reports have been published on the systemic administration of MSCs leading to functional improvements by engraftment and differentiation, thus providing a new strategy to regenerate damaged tissues. Recently, it has become clear that MSCs possess immunomodulatory properties and can therefore be used to treat diseases. However, the therapeutic effect mechanisms of MSCs are yet to be determined. Here, we investigated these mechanisms using a medication-related osteonecrosis of the jaw (MRONJ)-like mouse model. Methods: To generate MRONJ-like characteristics, mice received intravenous zoledronate and dexamethasone two times a week. At 1 week after intravenous injection, maxillary first molars were extracted, and at 1 week after tooth extraction, MSCs were isolated from the bone marrow of the mice femurs and tibias. To compare “diseased MSCs” from MRONJ-like mice (d-MSCs) with “control MSCs” from untreated mice (c-MSCs), the isolated MSCs were analyzed by differentiation and colony-forming unit-fibroblast (CFU-F) assays and systemic transplantation of either d-MSCs or c-MSCs into MRONJ-like mice. Furthermore, we observed the exchange of cell contents among d-MSCs and c-MSCs during coculture with all combinations of each MSC type. Results: d-MSCs were inferior to c-MSCs in differentiation and CFU-F assays. Moreover, the d-MSC-treated group did not show earlier healing in MRONJ-like mice. In cocultures with any combination, MSC pairs formed cell–cell contacts and exchanged cell contents. Interestingly, the exchange among c-MSCs and d-MSCs was more frequently observed than other pairs, and d-MSCs were distinguishable from c-MSCs. Conclusions: The interaction of c-MSCs and d-MSCs, including exchange of cell contents, contributes to the treatment potential of d-MSCs. This cellular behavior might be one therapeutic mechanism used by MSCs for MRONJ.Keywords
This publication has 40 references indexed in Scilit:
- Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cellsBMC Medicine, 2013
- Analysis of Mitochondrial Function and Localisation during Human Embryonic Stem Cell Differentiation In VitroPLOS ONE, 2012
- Characterization of bone marrow derived mesenchymal stem cells in suspensionStem Cell Research & Therapy, 2012
- Energy Metabolism in Nuclear ReprogrammingBiomarkers in Medicine, 2011
- Energy Metabolism in Human Pluripotent Stem Cells and Their Differentiated CounterpartsPLOS ONE, 2011
- Mitochondrial Function Controls Proliferation and Early Differentiation Potential of Embryonic Stem CellsStem Cells, 2010
- Mouse Mandible Contains Distinctive Mesenchymal Stem CellsJournal of Dental Research, 2010
- Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw–like disease in miceJournal of Bone and Mineral Research, 2010
- Pharmacologic Stem Cell Based Intervention as a New Approach to Osteoporosis Treatment in RodentsPLOS ONE, 2008
- Paracrine Factors of Mesenchymal Stem Cells Recruit Macrophages and Endothelial Lineage Cells and Enhance Wound HealingPLOS ONE, 2008